首页 / 院系成果 / 成果详情页

Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial 期刊论文

编号：

0a095e4c-0cf1-47ee-b83e-31ac2885b912
作者：

Wang, Guogan(王国干)#*^[1,2]Wang, Pengbo#^[1,2,3]Li, Yishi(李一石)^[2,4,5]Liu, Wenxian^[6];Bai, Shugong^[6];Zhen, Yang^[7];Li, Dongye(李东野)^[8]Yang, Ping(杨萍)^[9]Chen, Yu(陈宇)^[9]Hong, Lang(洪浪)^[10]Sun, Jianhui(孙建辉)^[11]Chen, Junzhu(陈君柱)^[12]Wang, Xian(王显)^[13]Zhu, Jihong(朱继红)^[14]Hu, Dayi(胡大一)^[14]Li, Huimin^[15];Wu, Tongguo^[16];Huang, Jie(黄洁)^[1,2]Tan, Huiqiong(谭慧琼)^[1,2]Zhang, Jian(张健)^[1,2]Liao, Zhongkai(廖中凯)^[1,2]Yu, Litian(于丽天)^[1,2]Mao, Yi(毛懿)^[1,2]Ye, Shaodong(叶绍东)^[1,2]Feng, Lei(丰雷)^[1,2]Hua, Yihong(华倚虹)^[1,2]Ni, Xinhai(倪新海)^[1,2]Zhang, Yuhui(张宇辉)^[1,2]Wang, Yang(王杨)^[17]Li, Wei(李卫)^[17]Luan, Xiaojun^[1,2];Sun, Xiaolu(孙筱璐)^[1,2]Wang, Sijia(王斯佳)^[1,2]
语种：

英文
期刊：

MEDICINE ISSN：0025-7974 2016 年 95 卷 9 期 ; MAR
收录：
摘要：

The aim of the study was to evaluate the efficacy and safety of 1-h infusion of recombinant human atrial natriuretic peptide (rhANP) in combination with standard therapy in patients with acute decompensated heart failure (ADHF).
This was a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Eligible patients with ADHF were randomized to receive a 1-h infusion of either rhANP or placebo at a ratio of 3: 1 in combination with standard therapy. The primary endpoint was dyspnea improvement (a decrease of at least 2 grades of dyspnea severity at 12 h from baseline). Reduction in pulmonary capillary wedge pressure (PCWP) 1 h after infusion was the co-primary endpoint for catheterized patients. Overall, 477 patients were randomized: 358 (93 catheterized) patients received rhANP and 118 (28 catheterized) received placebo. The percentage of patients with dyspnea improvement at 12 h was higher, although not statistically significant, in the rhANPgroup than in the placebo group (32.0% vs 25.4%, odds ratio = 1.382, 95% confidence interval [CI]: 0.863-2.212, P = 0.17). Reduction in PCWP at 1 h was significantly greater in patients treated with rhANP than in patients treated with placebo (-7.74 +/- 5.95 vs -1.82 +/- 4.47 mm Hg, P< 0.001). The frequencies of adverse events and renal impairment within 3 days of treatment were similar between the 2 groups. Mortality at 1 month was 3.1% in the rhANP group vs 2.5% in the placebo group (hazard ratio = 1.21, 95% CI: 0.34-4.26; P>0.99).
1-h rhANP infusion appears to result in prompt, transient hemodynamic improvement with a small, nonsignificant, effect on dyspnea in ADHF patients receiving standard therapy. The safety of 1-h infusion of rhANP seems to be acceptable.
推荐引用方式
GB/T 7714：

Wang Guogan,Wang Pengbo,Li Yishi, et al. Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial [J].MEDICINE,2016,95(9).
APA：

Wang Guogan,Wang Pengbo,Li Yishi,Liu Wenxian,&Wang Sijia.(2016).Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial .MEDICINE,95(9).
MLA：

Wang Guogan, et al. "Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial" .MEDICINE 95,9(2016).
入库时间：

12/4/2019 7:14:58 PM
更新时间：

12/4/2019 7:14:58 PM
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：90  下载次数：0

分享到：

浏览次数：90

下载次数：0

打印次数：0